Salesforce (CRM): Examining Valuation After AI Expansion, CrowdStrike Partnership, and UK Investment

If you’re a Salesforce (CRM) watcher, recent news might have you sitting up straighter at your desk. The company has taken bold steps forward on the AI front, expanding its Agentforce and Data Cloud platforms, forging a marquee partnership with CrowdStrike to secure AI-driven workflows, and boosting its investment in the UK with a $6 billion commitment. These moves suggest a clear ambition to lead in the evolving enterprise AI landscape, an area that’s becoming more critical by the month for large organizations worldwide.

Amid a backdrop of strong quarterly results, investor sentiment has generally trended positive. While Salesforce’s stock has pulled back about 11% over the past three months and remains down 26% for the year, the longer-term picture shows the company has generated significant value, returning over 71% in the past three years. This suggests momentum has cooled a bit in the short run, even as new AI-driven revenue streams gain traction and contracted bookings have continued to climb.

After this year’s correction, does Salesforce offer a compelling entry point for long-term investors, or is the market already expecting more growth than it can deliver?

Most Popular Narrative: 8.7% Overvalued

The prevailing narrative suggests Salesforce appears to be trading above its fair value, according to the latest extensive thesis by Goran_Damchevski. The narrative's in-depth analysis highlights several catalysts that could impact future valuation, but argues that current expectations may be outpacing what the company can realistically deliver in coming years.

The company improved profitability margins, with the operating margin rising by 2.8% to reach 20%, and the net margin of 16.1%, up by 24% vs 13% YoY. The company is incrementally increasing its profitability, and I am upgrading my estimates from 17.5% in 2028 to 20% in 2029.

What’s behind these bold numbers? This narrative leans on a handful of powerful assumptions including future margin expansion, ambitious revenue targets, and a valuation multiple typically reserved for market leaders. Curious which single financial bet moves the dial for Salesforce’s intrinsic value? Don’t miss what these projections reveal about the calculus behind the stock price.

Result: Fair Value of $223.99 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, unexpected enterprise wins or success in capturing small business customers could quickly shift momentum back in Salesforce’s favor, despite current concerns.

Find out about the key risks to this Salesforce narrative.

Another View: Discounted Cash Flow Says Undervalued

Taking a step back from valuations based on earnings multiples, our SWS DCF model arrives at a different conclusion. This approach points to Salesforce trading below its estimated fair value. Could the market be missing something here?

Look into how the SWS DCF model arrives at its fair value.

Stay updated when valuation signals shift by adding Salesforce to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Salesforce Narrative

If you see things differently or want to dig into the numbers firsthand, you can craft your personalized view of Salesforce’s story in just a few minutes. Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Salesforce.

Looking for More Investment Ideas?

Don’t let your next great opportunity pass you by. Use the power of the Simply Wall Street Screener to spot tomorrow’s winners beyond Salesforce.

• Tap into companies shaking up traditional finance by following the latest trends in digital currencies with our cryptocurrency and blockchain stocks.
• Uncover robust income opportunities by examining businesses known for reliably delivering dividend stocks with yields > 3% to shareholders year after year.
• Target game-changing innovations in healthcare by exploring firms leveraging artificial intelligence for smarter patient solutions in our healthcare AI stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com